Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Angelina Marr"'
Autor:
Nicolas Bruder, Randall Higashida, Hugues Santin-Janin, Cécile Dubois, E. François Aldrich, Angelina Marr, Sébastien Roux, Stephan A. Mayer
Publikováno v:
BMC Neurology, Vol 22, Iss 1, Pp 1-15 (2022)
Abstract Background For patients presenting with an aneurysmal subarachnoid hemorrhage (aSAH), delayed cerebral ischemia (DCI) is a significant cause of morbidity and mortality. The REACT study is designed to assess the safety and efficacy of clazose
Externí odkaz:
https://doaj.org/article/d6310e62d9c64dffab5591391eeeeb36
Autor:
Martin N. Stienen, Menno R. Germans, Olivia Zindel-Geisseler, Noemi Dannecker, Yannick Rothacher, Ladina Schlosser, Julia Velz, Martina Sebök, Noemi Eggenberger, Adrien May, Julien Haemmerli, Philippe Bijlenga, Karl Schaller, Ursula Guerra-Lopez, Rodolfo Maduri, Valérie Beaud, Khalid Al-Taha, Roy Thomas Daniel, Alessio Chiappini, Stefania Rossi, Thomas Robert, Sara Bonasia, Johannes Goldberg, Christian Fung, David Bervini, Marie Elise Maradan-Gachet, Klemens Gutbrod, Nicolai Maldaner, Marian C. Neidert, Severin Früh, Marc Schwind, Oliver Bozinov, Peter Brugger, Emanuela Keller, Angelina Marr, Sébastien Roux, Luca Regli, Niklaus Krayenbühl, Giuseppe Esposito, Alessandro Moiraghi, Daniele Starnoni, Alda Rocca, Martin A. Seule, Anna-Maria Zeitlberger, Astrid Weyerbrock, Martin Hlavica, Mandy Müller
Publikováno v:
Journal of neurosurgery. 137(6)
OBJECTIVE While prior retrospective studies have suggested that delayed cerebral ischemia (DCI) is a predictor of neuropsychological deficits after aneurysmal subarachnoid hemorrhage (aSAH), all studies to date have shown a high risk of bias. This st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ef25da84b70a9fabd707ca40286dbdf
https://pubmed.ncbi.nlm.nih.gov/35535839
https://pubmed.ncbi.nlm.nih.gov/35535839
Autor:
Sébastien Roux, Stephan A. Mayer, Abdel Hmissi, Nicolas Bruder, Elizabeth Le, E. Francois Aldrich, Angelina Marr, R. Loch Macdonald, Randall T. Higashida
Publikováno v:
Journal of neurosurgery. 134(5)
OBJECTIVE Aneurysmal subarachnoid hemorrhage (aSAH) is associated with significant morbidity and mortality. The presence of thick, diffuse subarachnoid blood may portend a worse clinical course and outcome, independently of other known prognostic fac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d39071b674f136b8859be873afaeae6
https://pubmed.ncbi.nlm.nih.gov/32442971
https://pubmed.ncbi.nlm.nih.gov/32442971
Autor:
Tanuwong Viarasilpa, Abdel Hmissi, E. Francois Aldrich, Nicolas Bruder, Stephan A. Mayer, Angelina Marr, R. Loch Macdonald, Randall T. Higashida, Sébastien Roux
Publikováno v:
Stroke. 50(10)
Background and Purpose— Clazosentan, an endothelin receptor antagonist, has been shown to reduce angiographic vasospasm and vasospasm-related morbidity after aneurysmal subarachnoid hemorrhage (SAH), although no effect on long-term functional outco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1304b5993baa5c4e491114822d5c9883
https://pubmed.ncbi.nlm.nih.gov/31394993
https://pubmed.ncbi.nlm.nih.gov/31394993
Autor:
Nicolas Bruder, Abdel Hmissi, Stefan Weidauer, Angelina Marr, Sébastien Roux, Randall T. Higashida, Rajiv Gupta, Stephan A. Mayer, Raphael Guzman, E. Francois Aldrich
Publikováno v:
World neurosurgery. 128
Background Clazosentan, an endothelin-1 receptor antagonist, has been shown to prevent the development of large vessel angiographic vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). It has been hypothesized that clazosentan can also reverse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac28f25776964ace05c09249f652dac6
https://pubmed.ncbi.nlm.nih.gov/31054336
https://pubmed.ncbi.nlm.nih.gov/31054336
Autor:
R Loch, Macdonald, Randall T, Higashida, Emanuela, Keller, Stephan A, Mayer, Andy, Molyneux, Andreas, Raabe, Peter, Vajkoczy, Isabel, Wanke, Doris, Bach, Aline, Frey, Angelina, Marr, Sébastien, Roux, Neal, Kassell
Publikováno v:
Acta neurochirurgica. Supplement. 115
We report here results of a randomized, double-blind, placebo-controlled study ( http://www.ClinicalTrials.gov , NCT00558311) that investigated the effect of clazosentan (5 mg/h, n = 768) or placebo (n = 389) administered for up to 14 days in patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d393d2ece66060fbec2bfb525560bf22
https://pubmed.ncbi.nlm.nih.gov/22890639
https://pubmed.ncbi.nlm.nih.gov/22890639
Autor:
Isabel Wanke, Neal F. Kassell, Andreas Raabe, Emanuela Keller, Peter Vajkoczy, Aline Frey, Andy Molyneux, Angelina Marr, R. Loch Macdonald, Randall T. Higashida, Sébastien Roux, Stephan A. Mayer, Doris Bach
Publikováno v:
Acta Neurochirurgica Supplement ISBN: 9783709111918
We report here results of a randomized, double-blind, placebo-controlled study (http://www.ClinicalTrials.gov, NCT00558311) that investigated the effect of clazosentan (5 mg/h, n = 768) or placebo (n = 389) administered for up to 14 days in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4406459a059623d00a3d7d8234782381
https://doi.org/10.1007/978-3-7091-1192-5_7
https://doi.org/10.1007/978-3-7091-1192-5_7
Autor:
Emanuela Keller, Peter Vajkoczy, Aline Frey, Neal F. Kassell, Angelina Marr, R. Loch Macdonald, Randall T. Higashida, Stephan A. Mayer, Sébastien Roux, Doris Bach, Andy Molyneux, Andreas Raabe, Isabel Wanke
Summary Background Clazosentan, an endothelin receptor antagonist, significantly and dose-dependently reduced angiographic vasospasm after aneurysmal subarachnoid haemorrhage (aSAH). We investigated whether clazosentan reduced vasospasm-related morbi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1168797fda9a68b08623b99f36bf00e1
https://www.zora.uzh.ch/id/eprint/50634/
https://www.zora.uzh.ch/id/eprint/50634/
Autor:
Angelina Marr, Neal F. Kassell, Andreas Raabe, R. Loch Macdonald, Randall T. Higashida, Isabel Wanke, Andy Molyneux, Doris Bach, Emanuela Keller, Sébastien Roux, Aline Frey, Peter Vajkoczy, Stephan A. Mayer
Korrespondenz zu 10.1016/S1474-4422(11)70189-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca86b3c4729aaa4c0b2e109c431f1ee1
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=80052990780
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=80052990780
Autor:
Sébastien Roux, Neal F. Kassell, Angelina Marr, R. Loch Macdonald, Emanuela Keller, Andy Molyneux, Randall T. Higashida, Peter Vajkoczy, Aline Frey, Isabel Wanke, Stephan A. Mayer, Andreas Raabe
Publikováno v:
Macdonald, R Loch; Higashida, Randall T; Keller, Emanuela; Mayer, Stephan A; Molyneux, Andy; Raabe, Andreas; Vajkoczy, Peter; Wanke, Isabel; Frey, Aline; Marr, Angelina; Roux, Sébastien; Kassell, Neal F (2010). Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials. Neurocritical care, 13(3), pp. 416-24. New York, N.Y.: Springer 10.1007/s12028-010-9433-3
Cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH) is a frequent but unpredictable complication associated with poor outcome. Current vasospasm therapies are suboptimal; new therapies are needed. Clazosentan, an endothelin receptor an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c148dbe64ddd9a736dde42a9df57b20
https://boris.unibe.ch/2292/1/s12028-010-9433-3.pdf
https://boris.unibe.ch/2292/1/s12028-010-9433-3.pdf